Hantz Financial Services Inc. Sells 139 Shares of STERIS plc (NYSE:STE)

Hantz Financial Services Inc. trimmed its position in STERIS plc (NYSE:STE) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 9,769 shares of the medical equipment provider’s stock after selling 139 shares during the period. Hantz Financial Services Inc.’s holdings in STERIS were worth $2,008,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of STE. West Coast Financial LLC lifted its holdings in shares of STERIS by 2.8% during the 3rd quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock worth $398,000 after acquiring an additional 45 shares during the period. SkyView Investment Advisors LLC lifted its stake in STERIS by 1.6% during the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock worth $765,000 after purchasing an additional 51 shares during the period. Park Edge Advisors LLC boosted its holdings in STERIS by 1.1% during the fourth quarter. Park Edge Advisors LLC now owns 4,662 shares of the medical equipment provider’s stock valued at $958,000 after purchasing an additional 51 shares in the last quarter. Central Pacific Bank Trust Division grew its stake in shares of STERIS by 65.5% in the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 76 shares during the period. Finally, Metis Global Partners LLC grew its stake in shares of STERIS by 1.6% in the 3rd quarter. Metis Global Partners LLC now owns 5,450 shares of the medical equipment provider’s stock valued at $1,322,000 after purchasing an additional 84 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analyst Ratings Changes

STE has been the topic of several recent analyst reports. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. JMP Securities reissued a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a report on Monday, November 18th. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $230.00 to $260.00 in a report on Thursday, October 24th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, Stephens restated an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and an average target price of $262.50.

Insiders Place Their Bets

In other news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares in the company, valued at $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.14% of the company’s stock.

STERIS Price Performance

Shares of STE stock opened at $221.66 on Friday. The stock’s fifty day moving average is $211.90 and its 200-day moving average is $224.77. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. STERIS plc has a 52 week low of $197.82 and a 52 week high of $248.24. The stock has a market capitalization of $21.88 billion, a PE ratio of 50.61 and a beta of 0.84.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The firm had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the prior year, the firm earned $2.03 EPS. The company’s revenue was up 7.3% on a year-over-year basis. Equities research analysts expect that STERIS plc will post 9.11 EPS for the current fiscal year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 1.03%. The ex-dividend date of this dividend is Thursday, February 20th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.